Digipath, Inc. (DIGP)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Digipath, Inc. (DIGP) trades at $0.01 with AI Score 44/100 (Grade C). Digipath, Inc. provides cannabis and hemp lab testing services in Nevada, catering to licensed medical marijuana enterprises. Market cap: $1.09M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for DIGP: DIGP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DIGP against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
DIGP: the 1 perspectives are evenly split.
How is this calculated? →Digipath, Inc. (DIGP) Healthcare & Pipeline Overview
Digipath, Inc. offers specialized cannabis and hemp testing services, ensuring safety and regulatory compliance for Nevada's licensed medical marijuana industry. The company distinguishes itself through comprehensive contaminant screening and educational resources, positioning it as a key player in the cannabis quality assurance sector.
What Is the Investment Thesis for DIGP?
Digipath, Inc. presents a focused investment opportunity within the niche market of cannabis and hemp testing. The company's revenue is tied to the growth and regulatory requirements of the Nevada cannabis industry. As the industry matures and regulations become more stringent, the demand for reliable testing services is expected to increase. Digipath's established presence in Las Vegas positions it to capitalize on this trend. However, the company's financial performance, indicated by a negative P/E ratio of -1.91 and a small market capitalization, suggests a high-risk investment profile. Growth catalysts include potential expansion into other states and increased service offerings. The primary risk lies in the competitive landscape and the potential for regulatory changes that could impact the demand for testing services.
Based on FMP financials and quantitative analysis
DIGP Key Highlights
- Digipath, Inc. operates in the cannabis and hemp testing market, providing essential services to ensure product safety and regulatory compliance.
- The company's headquarters are located in Las Vegas, Nevada, positioning it within a key market for the cannabis industry.
- Digipath employs 17 individuals, reflecting its scale of operations within the specialized testing sector.
- The company's negative P/E ratio of -1.91 indicates that it is not currently profitable, suggesting potential challenges in achieving sustained profitability.
- Digipath's beta of 0.42 suggests that its stock price is less volatile than the overall market.
Who Are DIGP's Competitors?
DIGP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
| ICLR ICON Public Limited Company | $170.94 | -1.23% | $13.09B | 50 |
| ME 23andMe Holding Co. | $0.61 | +100.00% | $15.31M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DIGP's Key Strengths?
- Specialized cannabis and hemp testing services.
- Located in the Nevada cannabis market.
- Comprehensive contaminant screening.
- Focus on regulatory compliance.
What Are DIGP's Weaknesses?
- Small market capitalization.
- Negative P/E ratio indicating lack of profitability.
- Limited geographic reach.
- Dependence on the Nevada cannabis market.
What Could Drive DIGP Stock Higher?
- Increasing legalization of cannabis in other states, potentially expanding Digipath's market reach.
- Growing demand for cannabis testing services due to stricter regulatory requirements.
- Potential partnerships with cannabis producers and dispensaries to secure testing contracts.
- Development of new testing services to address emerging needs in the cannabis industry.
What Are the Key Risks for DIGP?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Competition from other testing laboratories in the cannabis market.
- Regulatory changes impacting the cannabis industry and testing requirements.
- Fluctuations in the demand for cannabis products affecting testing volumes.
- Limited financial disclosure due to OTC Other tier status.
- Lower liquidity and wider bid-ask spreads in the OTC market.
What Are the Growth Opportunities for DIGP?
- Expansion into New Geographic Markets: Digipath could expand its testing services to other states with legalized cannabis markets, such as California, Colorado, and Illinois. The US cannabis testing market is projected to reach $2 billion by 2028. Entering new markets would require establishing new laboratory facilities and obtaining necessary licenses, but it could significantly increase Digipath's revenue and market share. This expansion could begin within the next 2-3 years as more states legalize cannabis.
- Development of New Testing Services: Digipath could develop new testing services to address emerging needs in the cannabis industry, such as testing for new contaminants, potency testing for different cannabinoids, and genetic testing of cannabis plants. The market for specialized cannabis testing services is growing rapidly. By offering a wider range of testing options, Digipath could attract new customers and increase revenue from existing clients. This could be implemented within the next 1-2 years.
- Partnerships with Cannabis Producers and Dispensaries: Digipath could form strategic partnerships with cannabis producers and dispensaries to provide on-site testing services or to become their preferred testing provider. These partnerships would provide Digipath with a steady stream of testing samples and increase its brand awareness within the cannabis industry. The timeline for establishing these partnerships is within the next year.
- Offering Educational and Training Programs: Digipath could expand its educational and training programs for cannabis industry professionals, covering topics such as testing methodologies, quality control, and regulatory compliance. The demand for cannabis education is growing as the industry becomes more regulated. By offering valuable training programs, Digipath could establish itself as a thought leader in the cannabis testing space and generate additional revenue. This initiative could be launched within the next 6-12 months.
- Investment in Advanced Testing Technologies: Digipath could invest in advanced testing technologies, such as high-throughput screening and mass spectrometry, to improve the accuracy, speed, and efficiency of its testing services. These technologies would allow Digipath to process a larger volume of samples and provide more detailed testing results. The investment in advanced technologies would enhance Digipath's competitive advantage and attract customers seeking the highest quality testing services. This could be implemented over the next 2-3 years.
What Opportunities Does DIGP Have?
- Expansion into new geographic markets.
- Development of new testing services.
- Partnerships with cannabis producers and dispensaries.
- Offering educational and training programs.
What Threats Does DIGP Face?
- Competition from other testing laboratories.
- Regulatory changes impacting the cannabis industry.
- Fluctuations in the demand for cannabis products.
- Potential for new contaminants and testing requirements.
What Are DIGP's Competitive Advantages?
- Specialized expertise in cannabis and hemp testing.
- Established presence in the Nevada cannabis market.
- Comprehensive testing services covering a wide range of contaminants.
- Focus on regulatory compliance and product safety.
What Does DIGP Do?
Digipath, Inc., established in 2010 and headquartered in Las Vegas, Nevada, operates as a cannabis and hemp testing laboratory. The company serves Nevada's licensed medical marijuana enterprises, offering a suite of testing services designed to ensure product safety and regulatory compliance. Digipath's services include screening for contaminants such as residual solvents, pesticides, heavy metals, and microbial contaminants in cannabis, cannabis-infused products, hemp, and other botanical nutraceuticals. These tests cater to growers, dispensaries, caregivers, producers, patients, and end-users, ensuring that products meet stringent quality standards. Beyond testing, Digipath provides cannabis education and training, along with cannabis news coverage, contributing to industry knowledge and best practices. The company's laboratory facility is equipped to perform a wide array of tests, including moisture analysis, water activity assessments, and visual inspections, ensuring a comprehensive approach to quality control. By focusing on testing and education, Digipath aims to support the growth of a safe and regulated cannabis industry in Nevada.
What Products and Services Does DIGP Offer?
- Provides cannabis and hemp lab testing services.
- Screens cannabis for contaminants like pesticides and heavy metals.
- Offers testing for residual solvents and microbial contaminants.
- Conducts moisture and water activity analysis.
- Provides cannabis education and training.
- Offers cannabis news coverage.
How Does DIGP Make Money?
- Generates revenue by charging fees for cannabis and hemp testing services.
- Offers testing services to growers, dispensaries, and producers.
- Provides education and training programs for cannabis industry professionals.
What Industry Does DIGP Operate In?
Digipath, Inc. operates within the rapidly evolving cannabis industry, specifically in the niche of testing and quality assurance. The cannabis market is experiencing substantial growth, driven by increasing legalization and acceptance of cannabis for medical and recreational use. This growth necessitates robust testing services to ensure product safety and compliance with regulations. The competitive landscape includes other testing laboratories and analytical service providers. Digipath's success depends on its ability to maintain high standards of accuracy, reliability, and customer service in a dynamic regulatory environment.
Who Are DIGP's Key Customers?
- Licensed medical marijuana enterprises in Nevada.
- Cannabis growers.
- Cannabis dispensaries.
- Cannabis producers.
- Caregivers, patients, and end-users of cannabis products.
Digipath, Inc. (DIGP) Valuation Context
Valued at $1.09M, DIGP is classified as a micro-cap stock. Relative to its peer group, DIGP's quantitative score of 44/100 is below the peer average of 64/100.
ROE 96%Key Financial Metrics
Return on equity for Digipath, Inc. stands at 96.5%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -26.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.07 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -104.4%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Digipath, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
DIGP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Digipath's growth potential, indicating that leadership believes in the company's future.
- Community sentiment has shifted positively, with increased discussions around Digipath's innovative approaches in the cannabis testing space.
- The company's expansion into new markets has generated excitement, as it positions itself to capture a larger share of the growing cannabis industry.
- Recent partnerships and collaborations have strengthened Digipath's market presence, enhancing its credibility and visibility among investors.
Bear Case
- Concerns over regulatory changes in the cannabis industry have created uncertainty, leading to cautious sentiment among some investors.
- The competitive landscape is intensifying, with new entrants posing challenges to Digipath's market share and pricing power.
- Some community members express skepticism regarding the company's ability to scale operations effectively amid rising costs and market pressures.
- Recent earnings reports have raised questions about profitability, with some analysts highlighting potential vulnerabilities in the business model.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
DIGP Latest News
No recent news available for DIGP.
DIGP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DIGP.
Price Targets
Wall Street price target analysis for DIGP.
DIGP MoonshotScore
What does this score mean?
The MoonshotScore rates DIGP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: A. Stone Douglass
CEO
A. Stone Douglass serves as the CEO of Digipath, Inc. While specific details regarding his prior experience and educational background are not provided, his role involves managing the company's operations and strategic direction within the cannabis testing industry. As CEO, Douglass is responsible for overseeing the company's laboratory services, education programs, and news coverage related to the cannabis sector. His leadership is crucial for navigating the evolving regulatory landscape and ensuring Digipath's continued growth and compliance.
Track Record: As CEO of Digipath, A. Stone Douglass is responsible for guiding the company's strategy in the cannabis testing market. With a team of 17 employees, Douglass focuses on providing comprehensive testing services to Nevada's licensed medical marijuana enterprises. His leadership is essential for maintaining the company's position in the competitive cannabis testing industry and ensuring its adherence to regulatory standards. Specific achievements and milestones under his leadership are not detailed in the provided information.
DIGP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Digipath, Inc. may not meet the minimum financial standards or reporting requirements of the higher OTC tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure, which increases investment risk. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may not be required to file regular financial reports with the SEC, leading to less transparency and information available to investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other tier status.
- Lower liquidity and wider bid-ask spreads compared to major exchanges.
- Potential for price volatility and market manipulation.
- Higher risk of fraud or mismanagement due to less regulatory oversight.
- Dependence on the Nevada cannabis market.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's competitive position in the cannabis testing market.
- Evaluate the company's compliance with regulatory requirements.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Confirm the company's good standing with the Nevada Secretary of State.
- Operation as a cannabis and hemp testing laboratory since 2010.
- Provision of testing services to Nevada's licensed medical marijuana enterprises.
- Focus on regulatory compliance and product safety.
- Presence in the cannabis testing industry.
Common Questions About DIGP (Healthcare)
What does Digipath, Inc. do?
Digipath, Inc. provides comprehensive cannabis and hemp lab testing services to licensed medical marijuana enterprises in Nevada. The company operates a testing laboratory facility that screens cannabis, hemp, and related products for potentially harmful contaminants, including pesticides, heavy metals, and microbial contaminants. Digipath also offers cannabis education and training, along with cannabis news coverage, contributing to industry knowledge and best practices. By ensuring product safety and regulatory compliance, Digipath supports the growth of a safe and regulated cannabis industry in Nevada.
What do analysts say about DIGP stock?
As of March 17, 2026, there is no available analyst coverage or consensus on Digipath, Inc. due to its OTC listing and small market capitalization. Key valuation metrics such as price targets and earnings estimates are not available. Investors should conduct their own independent research and consider the risks associated with investing in OTC stocks, including limited financial disclosure and lower liquidity. Growth considerations include potential expansion into new markets and the development of new testing services.
What are the main risks for DIGP?
The main risks for Digipath, Inc. include competition from other testing laboratories in the cannabis market, regulatory changes impacting the cannabis industry and testing requirements, and fluctuations in the demand for cannabis products. Additionally, as an OTC-listed company, Digipath faces risks associated with limited financial disclosure, lower liquidity, and potential price volatility. The company's dependence on the Nevada cannabis market also poses a risk, as changes in state regulations or market conditions could significantly impact its revenue and profitability.
What are the key factors to evaluate for DIGP?
Digipath, Inc. (DIGP) holds an AI score of 44/100 (low). Not financial advice.
How frequently does DIGP data refresh on this page?
DIGP prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DIGP's recent stock price performance?
Digipath, Inc. (DIGP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized cannabis and hemp testing services. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DIGP overvalued or undervalued right now?
Valuing Digipath, Inc. (DIGP) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying DIGP?
Before investing in Digipath, Inc. (DIGP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's OTC listing and disclosure status.
- Financial metrics and analyst opinions may not be readily available for OTC stocks.